Moffitt logo

Notice to Our Patients Regarding a Stolen Briefcase. Learn More

Clinical Trials Search

Clinical Trial 20313

Cancer Type: Cutaneous
Study Type: Treatment
NCT#: NCT04526730

Phase: Phase II
Prinicipal Investigator: Ahmad Tarhini

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma

Summary

This study is designed to evaluate the safety and efficacy of neoadjuvant immunotherapy of intratumoral tavo-EP in combination with intravenous (IV) nivolumab followed by surgery and adjuvant phase with nivolumab monotherapy in subjects with operable, locally-regionally advanced melanoma

Objective

To assess the complete pCR of intratumoral tavo-EP in combination with IV nivolumab (collectively the combined treatment) in subjects with operable locally-regionally advanced melanoma. To assess : (a) radiologic/clinical preoperative response rate (b) RFS and (c) OS. To assess safety and tolerability of the combined treatment as neoadjuvant therapy in subjects with operable locally-regionally advanced melanoma.

Treatments

Therapies

Medications

BMS-936558 (Nivolumab); Nivolumab (); Tavo-EP ()

Inclusion Criteria

  • Participant must be > 18 years of age
  • Histologic diagnosis of melanoma
  • Must be considered surgically operable
  • Have measurable disease based on RECIST v1.1, with at least one anatomically distinct lesion. Lesion or lesions must meet all the following baseline criteria:
  • a. Accessible for electroporation
  • b. Must be measured in at least one dimension (longest diameter in the plane of measurement is to be recorded)
  • c. Greater than 3 mm
  • Male Participants of childbearing potential must be surgically sterile, or must agree to use adequate method of contraception during the study and at least 5 months following the last day of study drug administration. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the Participant
  • Women of childbearing potential must have negative serum or urine pregnancy test within 72 hours prior to receiving the first study drug administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • For women of childbearing potential, must be willing to use an adequate method of contraception from 30 days prior to the first study drug administration and 5 months following last day study drug administration (either tavo or nivolumab); acceptable methods include hormonal contraception (oral contraceptives – as long as on stable dose, patch, implant, and injection), intrauterine devices, or double barrier methods (e.g. vaginal diaphragm/vaginal sponge plus condom, or condom plus spermicidal jelly), sexual abstinence or a vasectomized partner. Women may be surgically sterile or at least 1-year post-last menstrual period. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the Participant.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in protocol

  • Exclusion Criteria

  • Participant has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. Also, includes patients who are considered disease-free for at least 3 years from the last definitive treatment for a second malignancy.
  • Participants who have Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies at Screening). HIV testing at screening is not required unless considered clinically indicated by the treating physician.
  • Participants who have active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected at Screening); Note: Participants who have been vaccinated against Hepatitis B and who are positive only for the Hepatitis B surface antibody are permitted to participate in the study. Hepatitis B and C testing at screening is not required unless considered clinically indicated by the treating physician.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Principal Investigator.
  • Participant has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Participant has a history of interstitial lung disease.
  • Participant has an active infection requiring systemic therapy.
  • Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the Participant’s participation for the full duration of the trial, or is not in the best interest of the Participant to participate, in the opinion of the treating investigator.
  • Participant has not recovered (i.e., > Grade 1 at Cycle 1, Day 1) from AEs due to a previously administered agent.
  • Participant has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  • Participants who are pregnant or breast feeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 5 months after the last dose of trial treatment.
  • Participants with electronic pacemakers or defibrillators
  • Participants who have received a live-virus vaccination within 30 days of the first dose of treatment. Seasonal flu vaccines that do not contain live virus are permitted
  • Participants who have received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including G-CSF, GM-CSF or recombinant erythropoietin) within 4 weeks prior to study Cycle 1, Day 1
  • Previous treatment with anti-PD1 or anti-PDL1 immunotherapy
  • Participation in another clinical study and systemic therapy within 30 days of Cycle 1, Day 1.
  • ECOG Performance Status: >1
  • Inadequate organ function as defined by protocol
  • Participant has severe hypersensitivity (>Grade 3) to nivolumab and/or any of its excipients

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.